Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
Open accessAbstract
The prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body‐weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well‐being of people living with obesity. Treatment with amylin and calcitonin receptor agonists reduces food intake and induces weight loss in several animal models, and a number of companies have started clinical testing for peptide analogues in the treatment of obesity and/or type 2 diabetes. Studies predominantly performed in rodent models show that amylin and the dual amylin/calcitonin receptor agonist salmon calcitonin achieve their metabolic effects by engaging areas in the brain associated with regulating homeostatic energy balance. In particular, signalling via neuronal circuits in the caudal hindbrain and the hypothalamus is implicated in mediating effects on food intake and energy expenditure. We review the current literature investigating the interaction of amylin/calcitonin receptor agonists with neurocircuits that induce the observed metabolic effects. Moreover, the status of drug development of amylin and calcitonin receptor agonists for the treatment of metabolic diseases is summarized.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Amylin plays a role in signaling feelings of fullness, impacting both the body's energy balance mechanisms and pleasure-related brain regions centrally, while peripherally it delays gastric emptying and reduces the glucagon response after meals.
“This hormone plays a role in signaling feelings of fullness, impacting both the body's energy balance mechanisms and pleasure-related brain regions centrally, while peripherally it delays gastric emptying and reduces the glucagon response after meals (Boyle et al, 2018;Zakariassen et al, 2020).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Zakariassen et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 146 · Cited by 37
Research works printed but not linked: 1
- [143]143. Adis Insight. Dacra 089. 2019 [updated 2019; cited 2019 13 May]; Available from: https://adisinsight.springer.com/drugs/800052601.
- Authors
- Zakariassen, H. L., John, L. M., & Lutz, T. A.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk (Denmark) (DK)
- University of Zurich (CH)
- Corresponding author
- Zakariassen, Hannah Louise
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2020-05-18
- Volume
- 127
- Issue
- 3
- Pages
- 163-177
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W3023607311
- Cited by
- 37
- References
- 146
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 7
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Basic & Clinical Pharmacology & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF 31003 A_175458)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- amylin, salmon calcitonin, energy balance, obesity, type 2 diabetes, weight loss, dietary intake, energy expenditure, hypothalamus, caudal hindbrain, neural circuits, peptide analogues, drug development, metabolic disorders
- MeSH terms
- Animals, Energy Metabolism, Humans, Hypothalamus, Metabolic Diseases, Rhombencephalon, Receptors, Calcitonin, Leptin, Mice, Rats, Islet Amyloid Polypeptide, Amylin Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
